薬剤師が処方箋を出すのを拒むとき

Same author

Perspectives on Ethical Issues in Neurotechnology Industry-Academia Partnerships: Voices of Industry (Neuro)Ethicists.

AJOB neuroscience·2026

Same author

A Communitarian Ethics Approach to Ambient Intelligence Systems in Healthcare.

The American journal of bioethics : AJOB·2026

Same author

Bioethics in the Courtroom: Sketching Medicine with Integrity.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026

Same author

Clearing the Mist: The Distinct Roles of Transparency and Explainability for Using AI in Drug and Device Development.

Pharmaceutical medicine·2025

Same author

Artificial Intelligence (AI) Facts Labels: An Innovative Disclosure Tool Promoting Patient-Centric Transparency in Healthcare AI Systems.

Journal of medical systems·2025

Same author

Letter to the Editor - Reply to "Advancing AI Ethics Frameworks in Drug Development: Global Applicability, Practical Challenges, and Dynamic Governance".

Therapeutic innovation & regulatory science·2025

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

薬剤師が処方箋を出すのを拒むとき

関連する概念動画

Perspectives on Ethical Issues in Neurotechnology Industry-Academia Partnerships: Voices of Industry (Neuro)Ethicists.

A Communitarian Ethics Approach to Ambient Intelligence Systems in Healthcare.

Bioethics in the Courtroom: Sketching Medicine with Integrity.

Clearing the Mist: The Distinct Roles of Transparency and Explainability for Using AI in Drug and Device Development.

Artificial Intelligence (AI) Facts Labels: An Innovative Disclosure Tool Promoting Patient-Centric Transparency in Healthcare AI Systems.

Letter to the Editor - Reply to "Advancing AI Ethics Frameworks in Drug Development: Global Applicability, Practical Challenges, and Dynamic Governance".

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

薬剤師が処方箋を出すのを拒むとき

関連する概念動画

関連記事

Perspectives on Ethical Issues in Neurotechnology Industry-Academia Partnerships: Voices of Industry (Neuro)Ethicists.

A Communitarian Ethics Approach to Ambient Intelligence Systems in Healthcare.

Bioethics in the Courtroom: Sketching Medicine with Integrity.

Clearing the Mist: The Distinct Roles of Transparency and Explainability for Using AI in Drug and Device Development.

Artificial Intelligence (AI) Facts Labels: An Innovative Disclosure Tool Promoting Patient-Centric Transparency in Healthcare AI Systems.

Letter to the Editor - Reply to "Advancing AI Ethics Frameworks in Drug Development: Global Applicability, Practical Challenges, and Dynamic Governance".

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.